Evidence map›Paper›PMID 27704399›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).

J Capdevila, J C Galofré, E Grande, C Zafón Llopis, T Ramón Y Cajal Asensio, E Navarro González, P Jiménez-Fonseca, J Santamaría Sandi, J M Gómez Sáez, G Riesco Eizaguirre

Abstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  2. Real-world experience of clinicopathological features and survival predictors in radioactive iodine-refractory differentiated thyroid cancer treated with multi-kinase inhibitors: a multicentre study from southeastern Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Clinical and treatment patterns of advanced and radioiodine-refractory differentiated thyroid cancer. ERUDIT study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Journal of Cancer · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Evaluation of integrin αCancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. SEOM clinical guideline thyroid cancer (2019).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  19. Review
  20. lncRNA CASC2 EnhancesBioMed research international · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

J CapdevilaMedical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain. jacapdevila@vhebron.net.ORCID http://orcid.org/0000-0003-4592-3813
J C GalofréDepartment of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.
E GrandeMedical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
C Zafón LlopisDepartment of Endocrinology and Nutrition, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
T Ramón Y Cajal AsensioMedical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain.
E Navarro GonzálezDepartment of Endocrinology and Nutrition, Hospital Universitario Virgen del Rocío, Seville, Spain.
P Jiménez-FonsecaMedical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
J Santamaría SandiDepartment of Endocrinology and Nutrition, Hospital Universitario de Cruces, Vizcaya, Spain.
J M Gómez SáezCIBERDEM Service of Endocrinology and Nutrition, Hospital Universitario de Bellvitge, Barcelona, Spain.
G Riesco EizaguirreDepartment of Endocrinology and Nutrition, Hospital Universitario de Móstoles, Madrid, Spain.
Vall d'Hebron Hospital Universitari · ESBellvitge University Hospital · ESClinica Universidad de Navarra · ESHospital de Cruces · ESHospital de Sant Pau · ESHospital Universitario Central de Asturias · ESHospital Universitario de Móstoles · ESHospital Universitario Ramón y Cajal · ESHospital Universitario Virgen del Rocío · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid cancer (DTC) accounts for more than 90 % of all malignancies and its incidence has been rising steadily. For more patients, surgical treatment, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppressive therapy achieve an overall survival (OS) rate of 97.7 % at 5 years. Nevertheless, locoregional recurrence occurs in up to 20 % and distant metastases in approximately 10 % at 10 years. Two-thirds of these patients will never be cured with radioactive iodine therapy and will become RAI-refractory, with a 3-year OS rate of less than 50 %. Over the last decade, substantial progress has been made in the management of RAI-refractory DTC. Given the controversy in some areas, the Spanish Task Force for Thyroid Cancer on behalf of Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and the Spanish Rare Cancer Working Group (GETHI) have created a national joint task force to reach a consensus addressing the most challenging aspects of management in these patients. In this way, multidisciplinary management should be mandatory and nuclear medicine targeted therapy, novel molecular targeted agents, and combinations are currently changing the natural history of RAI-refractory DTC.

Indexed as

Iodine RadioisotopesCell DifferentiationDisease ManagementHumansMolecular Targeted TherapyPractice Guidelines as TopicProtein Kinase InhibitorsRadiation ToleranceThyroid NeoplasmsIodine RadioisotopesProtein Kinase InhibitorsDifferentiated thyroid cancerLenvatinibRadioactive iodine-refractory thyroid cancerReviewSorafenibTargeted therapyThyroid cancer

Identifiers

PMID27704399
OpenAlexW2528254735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.